

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application. Please cancel claims 1-9 without prejudice and add claims 10-17.

Claims 1-9 (canceled)

10. (new) A conjugate comprising insulin-like growth factor binding protein 4 and a constituent or constituents selected from the group consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa.
11. (new) The conjugate according to claim 1, wherein the single poly(ethylene glycol) group is a branched poly(ethylene glycol) group.
12. (new) The conjugate according to claim 1, wherein the two poly(ethylene glycol) groups are branched poly(ethylene glycol) groups.
13. (new) The conjugate according to claim 1, wherein only one of the two poly(ethylene glycol) groups is a branched poly(ethylene glycol) group.
14. (new) A conjugate according to claim 1 wherein the conjugate is linked to one or two poly(ethylene glycol) groups by a cysteine selected from the group consisting of: (1) cysteine 110; (2) cysteine 117; or (3) cysteine 110 and cysteine 117.
15. (new) A conjugate comprising insulin-like growth factor binding protein 4 and a constituent or constituents selected from the group consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa, comprising, reacting the insulin-like growth

factor binding protein 4 with activated (polyethylene) glycol under conditions such that said (polyethylene) glycol is chemically bound to said insulin-like growth factor binding protein 4 by primary amino groups or thiol groups of insulin-like growth factor binding protein 4.

16. (new) A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

17. (new) A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a conjugate comprising insulin-like growth factor binding protein 4 and a constituent or constituents selected from the group consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa.